Defective TFG-β signalling through the bone morphogen receptor type II is implicated in autosomal dominant and sporadic primary pulmonary hypertension. This fatal disorder is characterized by vascular remodelling, often triggered by the use of appetite-suppressant drugs which were, until recently, used to treat obesity.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
Purchase on Springer Link
Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Trembath, R.C. et al. Nature Genet. 26, 81– 84 (2000).
Nichols, W.C. et al. Nature Genet. 15, 277– 280 (1997).
Knowles, J.A. et al. Am. J. Hum. Genet. 67, 737– 744 (2000).
Nichols, W.C. et al. J. Med. Genet. (in press).
Massagué, J. & Chen, Y. Genes Dev. 14, 627–644 (2000).
Shovlin, C. J. Clin. Invest. 104, 1335–1336 (1999).
Lee, S.-D. J. Clin. Invest. 101, 927–934 (1998).
Lu, S.-L. Nature Genet. 19, 17–18 (1998).
Moore, L.G. N. Engl. J. Med. 333, 1248 (1995 ).
Aguirre, J.I. et al. Am. J. Physiol. 278, 981– 987 (2000).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Scott, J. Pulling apart pulmonary hypertension. Nat Genet 26, 3–4 (2000). https://doi.org/10.1038/79148
Issue Date:
DOI: https://doi.org/10.1038/79148
This article is cited by
-
To be or not to BMP
Nature Genetics (2001)